文献简介

出版社:Arch Dermatol Res (2016) 308:461–471

作  者:Sean M. Brady • Lee Shapiro • Shaker A. Mousa

编  号:

关键字:硬皮病

年  份:2016   点击量:15

文献摘要 全文翻译

Scleroderma is a heterogeneous disease with a complex etiology. As more information is gained about the underlying mechanisms and the improved classifications of scleroderma subtypes, treatments can be better personalized. Improving scleroderma patients’ early diagnosis before end organ manifestations occur should improve clinical trial design and outcomes. Two recently FDA-approved antifibrotics for idiopathic pulmonary fibrosis may be effective treatments in patients with pulmonary fibrosis secondary to scleroderma after further investigation. The potential impact of Nanobiotechnology in improving the efficacy and safety of existing antifibrotics and immunomodulators might present an exciting new approach in the management of scleroderma.

硬皮病是一种病因复杂的异质性疾病。随着对硬皮病潜在发病机制的了解和临床亚型分类的改善,治疗可以更加个性化。硬皮病患者在发生器官末端表现前的早期诊断的提高需改进临床试验设计和结果。最近对FDA批准的两种针对特发性肺纤维化的抗纤维化药物的进一步研究发现其可能是继发于硬皮病的肺纤维化患者的有效治疗方法。纳米生物技术在改善现有抗纤维药和免疫调节剂的功效和安全性方面的潜在影响,可能为硬皮病的治疗带来新的疗法。